Clinical trials
Adverse Drug Event clinical trials
Below are recruiting adverse drug event clinical trials, each written for real people, not researchers. We’re tracking 69 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07808866Recruiting
Computer and expert review of medicine reactions
This trial uses computers and multiple experts to study adverse drug reactions. They want to compare how well machines and humans can predict a dangerous reaction. If you have had a confirmed bad reaction to a medicine, your case may help improve future safety.
Beijing, Beijing MunicipalityAges Any age - NCT07794878RecruitingPhase 3
Comparing two fillers for smile line wrinkles
This trial tests two different dermal fillers to see how well they smooth out nasolabial folds (the lines from your nose to the corners of your mouth). Both fillers are already used for this purpose, and the study compares their effectiveness.
Beijing, Beijing MunicipalityAges 18 years+ - NCT01258231Recruiting
Genetic test to predict risks after heart surgery
This study looks for genetic (DNA) clues that may help predict side effects or complications after heart surgery. If you join, your genome information may be used to understand who is at higher risk and why.
Boston, MassachusettsAges 20–90 - NCT07769502RecruitingPhase 2
Treatment for advanced bile duct and pancreatic cancers
This trial is studying a new drug, telisotuzumab adizutecan, in combination with other treatments for advanced bile duct or pancreatic cancers. The goal is to see if the combination helps control the cancer. It's designed for people who are relatively active and can do their daily tasks.
Hattiesburg, MississippiAges 18 years+ - NCT07644897RecruitingPhase 2
Thymosin Alpha 1 Plus Anti-PD-1 for Advanced Melanoma in Older Adults
This trial tests a combination of two drugs—thymosin alpha 1 (an immune-boosting protein) and an anti-PD-1 antibody (a cancer immunotherapy)—in patients 60 and older with advanced melanoma that cannot be surgically removed. The goal is to help the immune system fight the cancer more effectively.
Guangzhou, GuangdongAges 60 years+ - NCT06278857RecruitingPhase 2
Dostarlimab for early-stage MMR deficient endometrial cancer
This trial tests the drug dostarlimab for patients with early-stage endometrial cancer that is MMR deficient. It aims to see if the treatment is safe and effective for those who want to preserve their uterus or cannot have surgery.
Sydney, New South WalesAges 18 years+ - NCT07581002RecruitingPhase 2/Phase 3
New AML Treatment With Three Drug Combination Study
This study tests a new three-drug combination (pivekimab sunirine, venetoclax, and azacitidine) for newly diagnosed acute myeloid leukemia in patients who cannot tolerate intensive chemotherapy. The goal is to see if this combination is safe and effective at controlling the disease.
Duarte, CaliforniaAges 18 years+ - NCT04840355Recruiting
Monitoring safety of sintilimab in Chinese patients
This study carefully tracks how safe sintilimab is for people with cancer in real-world care. It may help your care team understand side effects and risks during treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT06613165Recruiting
Short vs long treatment for stage II-III rectal cancer with dMMR
This trial tests how long you need a PD-1 immunotherapy before surgery for a specific type of rectal cancer (dMMR/MSI-H). It looks at whether a shorter or longer course works best. This could mean fewer side effects and a quicker path to surgery.
Xi'an, ShaanxiAges 18–80 - NCT07499128Enrolling by invitation
Continuous temperature monitoring for cytokine release syndrome
This study tests a wearable device that continuously monitors your body temperature to detect cytokine release syndrome, a possible side effect of certain immunotherapies. The goal is to catch it early so you can get treatment faster.
Bethesda, MarylandAges 18–120 - NCT07409246RecruitingPhase 1
Study of ABBV-438 for multiple myeloma patients
This trial tests a new intravenous treatment, ABBV-438, for adults with multiple myeloma that has returned or not responded to prior therapies. It aims to see if the drug is safe, tolerable, and how it moves through the body.
Duarte, CaliforniaAges 18 years+ - NCT07401303Recruiting
Studying a new way to reduce risks during early stomach cancer surgery
This trial tests a technique called full-time RDI during ESD (a minimally invasive procedure to remove early stomach cancer). The goal is to see if it can lower the chance of serious side effects and shorten the procedure time. If you are scheduled for this surgery and meet the health requirements, you may be able to join.
Xi'an, ShaanxiAges 18–75 - NCT07365241RecruitingPhase 3
Study of ABBV-706 vs standard care for advanced small cell lung cancer
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07276997RecruitingPhase 2
Study of Icalcaprant for major depressive disorder
This trial tests an oral medication called icalcaprant for adults with major depressive disorder (MDD). It aims to see if the drug can reduce depression symptoms and what side effects may occur.
Dothan, AlabamaAges 18–65 - NCT07241039RecruitingPhase 1
Study of an oral drug for advanced squamous cell cancers
This study tests an oral drug called ABBV-711, alone or with another drug, for adults with advanced squamous cell cancers of the head, neck, or lung that have stopped responding to standard treatments. It aims to see how safe and effective the drug is.
Duarte, CaliforniaAges 18 years+ - NCT07158814RecruitingPhase 4
Testing the safety of an RSV antibody in infants
This study checks if it is safe to delay the RSV preventive antibody shot by up to two weeks in infants who are getting their routine vaccines. Your baby will get the antibody at a second visit.
Oakland, CaliforniaAges 1 month–7 months - NCT07098351Recruiting
A trial for a new itchy skin medicine for people on peritoneal dialysis
This trial tests if a medication called nalfurafine hydrochloride (taken as a tablet that melts in your mouth) can help reduce moderate to severe itching in people receiving peritoneal dialysis for chronic kidney disease.
Guangzhou, GuangdongAges 18–85 - NCT07071532RecruitingPhase 1
Study of ABBV-932 with itraconazole for bipolar disorder
This study tests an investigational drug called ABBV-932 in people with bipolar disorder. It looks at how the drug moves through the body when taken with another medication (itraconazole) and checks for any side effects.
Los Alamitos, CaliforniaAges 18–65 - NCT07058454Recruiting
Heart safety study for targeted cancer therapies
This study looks at how targeted cancer treatments affect the heart. If you are an adult with any type of cancer and are getting or will get chemotherapy (including targeted drugs), joining this study helps doctors understand heart risks better.
Guangzhou, GuangdongAges 18 years+ - NCT07044687RecruitingPhase 4
Venetoclax with azacitidine for newly diagnosed AML
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
Gurgaon, HaryanaAges 18 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT05663775RecruitingPhase 2
Mesalamine to prevent bowel inflammation after melanoma immunotherapy
This study tests whether taking mesalamine can prevent colitis (bowel inflammation) in people with advanced melanoma who are treated with ipilimumab plus nivolumab. It may help reduce dangerous stomach or bowel side effects from this cancer treatment.
Edmonton, AlbertaAges 18 years+ - NCT06858813RecruitingPhase 1
ABBV-324 for advanced liver or lung cancer
This study tests an experimental IV drug (ABBV-324) for adults with advanced liver cancer (HCC) or advanced squamous lung cancer (LUSC). It aims to see if the drug is safe and whether it can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06820970Recruiting
Combined therapy for heart artery blockages that weren't fully opened
This trial tests if combining a new heart procedure with a special type of therapy called mindfulness therapy can help prevent heart problems in people with coronary artery disease that could not be fully fixed with stents or surgery.
Zhengzhou, HenanAges 18 years+
Hear when a new Adverse Drug Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adverse drug event?
- Yes. Clin2 currently lists 69 recruiting adverse drug event studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adverse drug event trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adverse drug event trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.